Sunbeam Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 6.10 Cr
as on 24-10-2024
- Paid Up Capital ₹ 6.00 Cr
as on 24-10-2024
- Company Age 9 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 29.43 Cr
as on 24-10-2024
- Satisfied Charges ₹ 11.17 Cr
as on 24-10-2024
- Revenue 32.34%
(FY 2023)
- Profit 33.44%
(FY 2023)
- Ebitda 36.91%
(FY 2023)
- Net Worth 60.47%
(FY 2023)
- Total Assets 40.98%
(FY 2023)
About Sunbeam Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.10 Cr and a paid-up capital of Rs 6.00 Cr.
The company currently has active open charges totaling ₹29.43 Cr. The company has closed loans amounting to ₹11.17 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sowrinathan, Vazhi Eratnasababathi, Kamalakannan Veerabadran, and One other member serve as directors at the Company.
- CIN/LLPIN
U52339PY2015PTC008465
- Company No.
008465
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Apr 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pondicherry
Industry
Company Details
- Location
Villupuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Sunbeam Lifesciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sowrinathan  | Director | 26-Jun-2017 | Current |
| Vazhi Eratnasababathi | Director | 08-Apr-2015 | Current |
| Kamalakannan Veerabadran | Director | 26-Jun-2017 | Current |
| Sivapragasam | Director | 01-Apr-2016 | Current |
Financial Performance of Sunbeam Lifesciences.
Sunbeam Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 32.34% increase. The company also saw a substantial improvement in profitability, with a 33.44% increase in profit. The company's net worth Soared by an impressive increase of 60.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sunbeam Lifesciences?
In 2023, Sunbeam Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 27 Mar 2024 | ₹2.00 Cr | Open |
Hdfc Bank Limited Creation Date: 22 Mar 2024 | ₹2.23 M | Open |
Sidbi Creation Date: 14 Dec 2023 | ₹1.04 Cr | Open |
How Many Employees Work at Sunbeam Lifesciences?
Sunbeam Lifesciences has a workforce of 49 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sunbeam Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sunbeam Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
